Recipharm appoints Chief Strategy Officer

Recipharm, the leading contract development and manufacturing organisation, is
pleased to announce that it has appointed Jean-François Hilaire to the new
position of Chief Strategy Officer to join Recipharm’s Group Management Team
with effect from today.
Jean-François Hilaire is a pharmacist and graduated from the university of
Bordeaux and alumni of the CEDEP General Manager Program (campus INSEAD –
Fontainebleau). He brings a broad experience base acquired in Commercial as well
as in Manufacturing & Supply leadership roles at Fournier, Solvay and Abbott.

Commenting on the appointment, Thomas Eldered CEO said “Jean- François Hilaire
will bring valuable and relevant experience from the pharmaceutical industry in
general but also very important views from outsourcing of pharmaceutical
development and manufacturing”.

Jean-François said “I am glad to be joining Recipharm and its leadership team
whom I have had the chance to know for several years and admire their
entrepreneurship. Furthermore, with the current transformation of the
pharmaceutical industry, I see Recipharm as very well positioned to catch
sizable business opportunities in extending the value created for its
customers“.

For more information please visit www.recipharm.com or contact:
Thomas Eldered, CEO Recipharm, thomas.eldered@recipharm.com, + 46 8 602 52 10
Jean-François Hilaire, CSO Recipharm, jean-francois.hilaire@recipharm.com, +33
695 44 7507

For media enquiries, please contact Tristan Jervis or Alex Heeley at De Facto
Communications on:
E-mail: t.jervis@defacto.com  (t.jervis@defacto.com%20)or a.heeley@defacto.com
Tel: +44 (0) 207 861 3019/3043

This information is published in accordance with the Swedish Securities Market
Act, the Swedish Financial Instruments Trading Act and/or the regulations of
NASDAQ Stockholm. This information was submitted for publication on 1 June 2015,
at 10:00 am CET.

About Recipharm
Recipharm is a leading CDMO (Contract Development and Manufacturing
Organisation) in the pharmaceutical industry employing some 2,200 employees.
Recipharm offers manufacturing services of pharmaceuticals in various dosage
forms, production of clinical trial material including API and pharmaceutical
product development. Recipharm manufactures more than 400 different products to
customers ranging from Big Pharma to smaller research- and development
companies. Recipharm’s turnover is approximately SEK 3.3 billion and the Company
operates development and manufacturing facilities in Sweden, France, the UK,
Germany, Spain, Italy and Portugal and is headquartered in Jordbro, Sweden. The
Recipharm B-share (RECI B) is listed on NASDAQ Stockholm.

For more information on Recipharm and our services, please visit
www.recipharm.com